The objective of this study was to determine the empirical efficacy of imidacloprid 10 %/flumethrin 4.5 % (Seresto ® ) collars in preventing long-term transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs. The study was a parallel group design, single centre, randomised, non-blinded, controlled, long-term efficacy study. The treatment group of 8 dogs was fitted with Seresto ® collars, the untreated control group of 8 dogs received no collars. Ehrlichia canis-infected ticks were released into the dogs sleeping quarters at 14-day intervals up to Day +378. Control group dogs infected with E. canis were continuously replaced to keep the control sample size constant, and a total of 39 control dogs were required. The final clinical examination and blood sampling occurred on Day +420. The primary assessment criterion was the number of dogs infected with E. canis, as confirmed by IFA and PCR, and the secondary criterion was the acaricidal efficacy based on tick counts. All scheduled blood samples taken were subject to analyses for both PCR and IFA, but only positive cases are discussed. Up to Day +378, none of the collar-treated dogs were infected with E. canis, whereas 34 of the 35 untreated dogs enrolled before Day +371 were infected. The acaricidal efficacy of the collar ranged from 90 % to 100 % for the duration of the assessment period.
Introduction
Ticks are common ectoparasites present in many areas of the world. Rhipicephalus sanguineus is the most common tick species in subtropical and tropical regions as well as being one of the main European tick species (Otranto et al. 2008; Stanneck et al. 2012) . R. sanguineus is responsible for the transmission of Ehrlichia canis to dogs, which causes canine monocytic ehrlichiosis (CME), the most well-known globally occurring canine tickborne disease (Otranto et al. 2008) . Dogs with CME present a wide range of clinical symptoms, including weight loss, lethargy, anorexia, pyrexia, lymphadenomegaly and splenomegaly (Harrus et al. 1997) . Occular signs such as corneal opacity may also occur and subretinal haemorrhages can lead to blindness (Harrus et al. 1998 ). The imidacloprid 10 %/flumethrin 4.5 % collar (Seresto ® ) contains a combination of the acaricide flumethrin with the insecticide imidacloprid. Flumethrin is a highly potent acaricide, which has been registered for animal use since 1986 and has been used as an active ingredient in the companion animal product "Kiltix ® " collar (propoxur 10 %/ flumethrin 2.25 %) for over 15 years (Liebisch et al. 1996) . The newer Seresto ® collar has been available commercially since 2012 and the active ingredients have been shown to spread from the collar over the entire skin surface of the treated animal (Stanneck et al. 2012a ). The imidacloprid 10 %/flumethrin 4.5 % collar has been shown to be safe and highly effective in the treatment and prevention of tick and flea infestations in cats and dogs. It has been proven to reduce tick counts by at least 90 % in cats and dogs under field conditions for a period of at least 7-8 months (Stanneck et al. 2012b) . Though the time frame of E. canis transmission by R. sanguineus ticks was not part of this study, it is known from current literature that rickettsial pathogens can be transmitted from ticks to dogs within a short time frame of just 4 hours (Nicholson et al. 2010) . It is therefore important to determine whether the imidacloprid 10 %/flumethrin 4.5 % collars act fast enough to prevent R. sanguineus ticks from infecting dogs with E. canis. The aim of this study was to empirically evaluate the long-term efficacy of the Seresto ® collar formulation in preventing the transmission of E. canis to dogs by infected R. sanguineus ticks.
Materials and methods

General study design
This study was conducted in South Africa and lasted from December 2011 to February 2013; the last blood collection and clinical examination was on Day +420. The study was a parallel group design, single centre, randomised, non-blinded, controlled, long-term efficacy study conducted on two groups each containing eight dogs. Untreated control group dogs diagnosed with CME during the study were replaced to ensure that the control group po pulation remained constant for the duration of the experimental phase. The sample size of eight dogs per group is compliant with the CVMP guideline "Guidelines for the Testing and Evaluation of the Efficacy of Antiparasitic Substances for the Treatment and Prevention of Tick and Flea Infestations in Dogs and Cats". Acclimatisation, ranking, collar administration and clinical examinations were performed at the time intervals shown in Table 1 . Collars were replaced at Day 155 to provide a full year of collar protection during the study with the second treatment period ending after the collars' registered 8 months maximum efficacy period. In order not to have the last month of collar efficacy in the middle of the study, an earlier retreatment after 155 days instead of 8 months was chosen. The approximate one-year study duration was designed to mimic an animal under full-year protection in a hyperendemic area with tick exposure throughout the whole year, as it may occur in southern Mediterranean areas.
Subjects and randomisation
Healthy male and female beagle dogs over 4 months in age, with a body weight of between 8 kg and 25 kg and complying with predefined inclusion/exclusion criteria were used. All dogs were dewormed, harboured no ticks at the initiation of the study and were sero-negative for E. canis prior to the acclimatisation period. None of the dogs had been treated with a topical or systemic acaricide/insecticide 12 weeks prior to acclimatisation start. Dogs were identified by electronic transponders with unique alphanumeric codes. The study followed a randomised block design and the Day -2 body weight of each dog was used for ranking and group allocation purposes. The 16 dogs initially included were ranked, within gender, in descending order of individual body weights. Animal ID's were used to break ties. Within each gender, animals were then blocked into replicates of two dogs each. Within each replicate, dogs were randomly allocated to groups 1 (untreated group) or 2 (treated group).
Dose and administration of the investigational veterinary product
The investigational veterinary product (IVP) was the imidacloprid 10 %/flumethrin 4.5 % collar which was fitted according to label instructions on Days 0 and +155 to the dogs in group 2. Dogs in the untreated group were not fitted with placebo collars.
Tick infestation and tick counts
A laboratory-bred R. sanguineus tick strain infected with E. canis was used for the artificial challenges in the kennel environment. Infectivity of ticks was confirmed by PCR analysis on a sample of between 30-40 R. sanguineus ticks taken from each batch of ticks to be used for the artificial challenges. The infectivity of the ticks used for the challenges ranged from approximately 2-17 %. For the first tick challenge (on Day +14), 20 ticks were used. But this amount resulted in a low tick burden, so it was decided to increase the number of ticks to 50 to improve the tick challenge. Therefore, from the second challenge (Day +28) onwards, 50 ticks were used. Ticks were released in the sleeping kennels of the dogs and the exact number of ticks used during each challenge was recorded. The ticks used were adult, unfed, at least one week old and had a balanced sex ratio of 1:1 of female and male, respectively. Tick counts were in situ on all days except Day +380 when ticks were removed and counted. The findings of the tick counts were categorised as shown in Table 3 . Blood collection for PCR analysis Blood was collected from treated and control groups as shown in Table 4 . Blood for PCR analysis was collected in EDTA tubes. Blood samples for PCR analysis were tested at ClinVet International (Pty) Ltd. All blood samples taken during scheduled sampling occasions were subject to analysis, but only positive cases are discussed. In cases where clinical signs associated with ehrlichiosis were observed, samples were also taken for PCR and platelet counts only. Total genomic DNA was isolated from whole blood samples using a commercial genomic DNA isolation kit. Polymerase chain reaction entailed the use of primers specific to a region of the E. canis dsb gene. Up to 400 ng DNA extracted from whole blood served as template for PCR amplification of the target region. PCR products were analysed using agarose gel electrophoresis. A PCR product of approximately 500 bp indicated the presence of the E. canis dsb target region in the sample. Positive, negative, no template, as well as internal amplification controls were included in each run to validate the reactions.
Serum collection for IFA analysis
At least 7 ml of blood was collected from all dogs on days indicated in Table 4 . Serum was recovered from the plain tubes, divided into primary and duplicate aliquots and frozen at < -35 °C until assayed for E. canis antibodies using a commercial IFA test (IGG IFA, Fuller Laboratory) performed according to the manufacturer's description by the Department of Veterinary Tropical Diseases (DVTD), Faculty of Veterinary Science, University of Pretoria, South Africa. All blood samples taken during scheduled sampling occasions were subject to analysis, but only positive cases are discussed.
Dog welfare and monitoring of clinical signs associated with ehrlichiosis
Body temperatures: Rectal body temperatures were recorded for all dogs twice weekly (at least 2 days apart) starting from Day +28 onwards. Rectal body temperatures for dogs with abnormally high values (> 39.4 °C) were additionally measured the following day again and if still abnormally high, a clinical examination was conducted. Blood was also collected for platelet counts from these dogs. Table 4 Time points for blood and serum collection
Blood collection* Serum collection
Days +28, +42, +56, +70, +84, +98, +112, +126, +140, +154, +168, +182, +196, +210, +224, +238, +252, +266, +280, +294, +308, +322, +336, +350,+364, +378, +392, +406 and +420
Prior to study inclusion and Days +42, +70, +98, +126, +154, +182, +210, +238, +266, +294, +332, +350, +378 and +406 * Blood was collected from dogs that had not yet been diagnosed and treated for ehrlichiosis and additionally from all dogs with a body temperature of > 39.4 °C for two consecutive days Platelet counts: Blood for platelet counts was collected in EDTA tubes on days indicated in Table 4 . EDTA blood samples for platelet counts were examined at Pathcare Veterinary Laboratory, Bloemfontein, South Africa.
Clinical examinations:
The study dogs were subjected to a clinical examination on the days specified in Table 1 . The clinical examination included general appearance by body system, respiration rate, heart rate and body temperature. Additionally, clinical examinations were conducted on all dogs displaying clinical signs associated with CME, such as fever, depression, anorexia, weight loss, haemorrhages, epistaxis and gastrointestinal signs such as diarrhoea. Dogs with abnormally high body temperatures (> 39.4 °C) and dogs with CME-associated clinical signs as observed during the routine daily observations were examined by the veterinarian. To prevent fatal ehrlichiosis, dogs with abnormally high body temperatures (> 39.4 °C) for at least two consecutive days and an abnormally low platelet count were rescue-treated with doxycycline if judged necessary by the examining veterinarian.
General health observations
All animals were observed daily (from Day -7 to +420) for general health conditions and clinical signs of adverse reactions to treatment. Dogs displaying any abnormal signs were examined by a veterinarian.
Statistical analysis
The primary statistical assessment criterion was the number of dogs infected with E. canis in the untreated control and the treated group. The secondary statistical assessment criterion was the acaricidal activity of the collar as shown by the number of live ticks collected from the untreated control and the treated group on the various count days. The level of significance of the formal tests was set at 5 % and all tests were two-sided. The groups were compared using an ANOVA with a treatment effect after a logarithmic transformation on the tick (count + 1) data. Calculation of acaricidal activity of the collar Efficacy against ticks was calculated for the treatment group at each assessment day according to the formula given below. Due to the fact that small and even zero tick counts were recorded, it was expected that the tick counts would not follow a normal distribution. Therefore, it was decided that the primary efficacy calculations would be based on geometric means rather than arithmetic means. The calculations were based on the geometric means of the tick (count + 1) data. One (1) was subsequently subtracted from the result to obtain a meaningful value for the geometric mean of each treatment group. Efficacy calculations based on arithmetic means were, however, also reported. Percent efficacy against ticks was calculated as follows:
Efficacy (%) = 100 x (Gmc -Gmt) / Gmc Gmc = Geometric or arithmetic mean number of live ticks (categories 1-3, as explained in Table 3 ) on dogs in the negative control group (group 1) at a specific time point Gmt = Geometric or arithmetic mean number of live ticks and dead ticks (categories 1-3 and 6) in the treatment group (group 2) at a specific time point
Results
PCR Results
Ehrlichia canis DNA was detected in four collartreated dogs of which an infection could only be confirmed in two of these dogs by IFA assay. E. canis DNA was detected in 36 out of the 39 untreated control dogs throughout the study experimental phase.
IFA results
Up to Day +350, no E. canis antibodies were detected in any of the collar-treated dogs. Sero-conversion was, however, observed in three collar-treated dogs on Day +378 and in two dogs on Day +406. During the course of the experimental phase, 39 untreated control dogs were exposed to the environmental tick challenge of which only one dog did not seroconvert by Day +406.
Ehrlichia canis blocking efficacy
Infections with E. canis were confirmed by IFA and PCR in 2 collar-treated dogs and 36 untreated dogs over the 420 day assessment period. Infection with E. canis was, however, only first confirmed in the two collar dogs on Day +378. The IVP collar, therefore, reduced the risk of infections by 100 % up to Day +378 and by 94.4 % up to Day +420.
Tick count results
Low tick burdens were observed on the dogs during the in situ tick counts on Day +14, so the number of ticks used for subsequent challenges was increased from 20 to 50. This change was assessed as having no negative impact on the study and improved the tick challenges on dogs. Arithmetic and geometric mean tick counts on the various assessment days for the two study groups are summarised in Table 5 . The arithmetic mean tick counts recorded for the negative control group ranged from 1.5 to 29.0. The geometric mean tick counts recorded for the treatment groups differed statistically significantly (p < 0.05) from that of the untreated control group (group 1) on all assessment days.
Acaricidal activity results
Efficacy values of acaricidal activity (%) based on arithmetic and geometric mean tick counts are summarised in Table 5 . Efficacies based on geometric means were considered primary. The IVP collar was highly effective against R. sanguineus ticks in a simulated kennel environment with efficacies ranging from 90.0-100 % for the duration of the assessment period.
Dog welfare and clinical signs associated with ehrlichiosis discussion
Of the control and treated groups totalling 39 and 8 dogs, respectively, 28 control dogs and two treated dogs had to be rescue-treated for ehrlichiosis. All dogs recovered completely.
Body temperatures
The body temperature ranges recorded during the routine measurements (excluding those conducted during clinical examinations) for the dogs included in the study experimental phase are summarised in Table 6 . Elevated body temperatures (> 39.4 °C) were observed in two collar-treated dogs and 25 of the 39 untreated control dogs exposed to the environmental tick challenges. Infection with E. canis was confirmed in all dogs with elevated body temperatures.
Platelet counts
The platelet counts are summarised for all dogs in Table 6 . Low platelet counts were observed an all but two dogs confirmed infected with E. canis.
Clinical examinations
The abnormal clinical signs generally associated with ehrlichiosis observed during the clinical observation conducted at a minimum every two weeks are summarised in Table 7 . The most common abnormal clinical signs observed were enlarged superficial, submandibular and popliteal lymph nodes. 
General health observations
The signs recorded from dogs during the daily general health observations are summarised in Table 8 . All of the signs were seen in group 1 dogs and are associated with ehrlichiosis. Dogs received appropriate veterinary care.
Adverse events
No adverse events occurred during the clinical examinations and daily health observations which were regarded as being related to the administration of the collar. 
Discussion and conclusion
The study reported here was conducted in the spirit of the VICH GL9 (July 2000) guideline on good clinical practice to assure high quality standards. The study was controlled and the animals were randomised. The control group animals were not fitted with placebo collars, so blinding was not possible, but the possibility of bias was considered to be minimal as IFA, PCR and tick counts are objective standardised procedures. Also the 2 % to 17 % prevalence of E. canis infection in the ticks used for the challenges was regarded as representative for field situations, as prevalences of E. canis in ticks reported from different endemic areas (either mammalian hosts or questing adults in the environment) vary between 0.09 % and 10 % (Aguiar et al. 2007; Satta et al. 2011; Harrus et al. 2011) . The primary objective was the transmission prevention ability for E. canis and, therefore, the number of dogs infected by E. canis. None of the Seresto ® collar-treated dogs were infected for the first year of the study, despite being subjected to 216 infestation events (= animals x infestation time points). Towards the end of the experimental phase (Day +378), two collar-treated dogs were infected by E. canis as confirmed by PCR and IFA. By contrast, dogs in the control group had to be replaced frequently due to E. canis infections, necessitating a total of 39 dogs for the complete experimental phase. Of these 39, 36 became infected as confirmed by IFA and PCR. The secondary objective was the acaricidal efficacy based on tick counts. The geometric mean tick count for the collar-treated dogs was low and ranged from 0.0 (at the first ten time points) to 1.5 during the entire assessment period. In comparison, the geometric mean tick count for untreated dogs was considerably higher and ranged from 1.4 (at the first time point when only 20 ticks were used to challenge) to 29.0 during the same period. Acaricidal efficacies ranged from 90.0 % to 100 % for the entire assessment period. In summary, the empirical efficacy of the Seresto ® collar in preventing long-term transmission of E.canis by infected R. sanguineus ticks to dogs has been evaluated for the first time. The collar prevented E. canis transmission by 100 % up to Day +378 (197 days after the most recent collar application) and by 94.4 % up to Day +420 (223 days after the most recent collar application). Acaricidal efficacy ranged from 90.0 % to 100 %. These results show that the collar is not only effective at killing R. sanguineus, but also that the onset of acaricidal action is quick enough to prevent ticks from transmitting the E. canis infection over a time period consistent with the label efficacy period of 8 months.
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